Furthermore, LKB1 silencing diminishes the sensitivity of KRASG12C/LKB1Null-driven lung cancer to KRASG12C inhibition perhaps through the emergence of mixed adenosquamous cell carcinomas and mucinous adenocarcinomas. Here, STK11 is linked to lung carcinoma.